Sign up to save your podcasts
Or
Share This Pharma Company Is Betting Big On A Chinese Ozempic Rival
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
This Pharma Company Is Betting Big On A Chinese Ozempic Rival
Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is quickly emerging as a powerhouse pharmaceutical R&D center.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
View all episodes
4.2
1313 ratings
Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is quickly emerging as a powerhouse pharmaceutical R&D center.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
More shows like Forbes Daily Briefing
View all
WSJ Your Money Briefing
1,714 Listeners
WSJ What’s News
4,352 Listeners
Bloomberg Intelligence
410 Listeners
Bloomberg Businessweek
424 Listeners
WSJ Tech News Briefing
1,634 Listeners
WSJ Minute Briefing
673 Listeners
Bold Names
1,449 Listeners
Wall Street Breakfast
1,032 Listeners
Steve Forbes: What's Ahead
505 Listeners
Here's Why
69 Listeners
Barron's Streetwise
1,553 Listeners
AP Newswatch: Top Stories from the Associated Press
54 Listeners
Barron's Live
208 Listeners
The Big Take
155 Listeners
Forbes Talks
6 Listeners
Forbes Newsroom
3 Listeners